Semnur Pharmaceuticals, Inc. (SMNR) stock: key figures, P/E, revenue and dividend
Health Care · United States
Semnur Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -160.42 m USD |
| EBIT | -160.42 m USD |
| Net income | -160.42 m USD |
| Diluted EPS – continuing operations | -0.78 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
More stocks
- RoyalTek Co Ltd (3306.TWO)
- Mevaco S.A (MEVA.AT)
- Pender Growth Fund VCC Inc (PTF.V)
- PADAUK Technology Co. Ltd (6716.TWO)
- Mdevice (226590.KQ)
- Korea Flange (010100.KS)
- Magna Prima Bhd (7617.KL)
- 1895 Bancorp of Wisconsin, Inc. /MD/ (BCOW)
- Norse Atlantic ASA (NORSE.OL)
- ME2ZEN Limited (950190.KQ)
- Global Connections Public Company Limited (GC.BK)
- Vetnostrum Animal Health Co., Ltd. (6936.TW)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.